Belgium· BE-AMP-SAM301856-00
Soliris 300 mg
A eculizumab product containing eculizumab, registered in Belgium by Alexion Europe. The same ATC class is registered in 13 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Eculizumab is registered in 13 of 19 countries.
Countries holding a registration under ATC L04AJ01 (eculizumab), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 8 of them publish a price we can compare per daily dose
Eculizumab · ATC L04AJ01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Eculizumab
- Manufacturer
- Alexion Europe
- Country
- Belgium (BE)
- ATC code
- L04AJ01
- ATC class
- Eculizumab
- Defined daily dose
- 64 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb0792697
- be_apb2601565
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
2 interactions on record for eculizumab.
Graded by severity as the source publishes them — 2 minor. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Eculizumab · interactions on record
2 records
Same medicine, other countries
Eculizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NorwayBekemvAmgen Technology Ireland
- CzechiaBEKEMVAmgen Europe B.V., Breda
- FinlandBEKEMVAmgen Europe B.V.
- IrelandBEKEMV 300 mg Concentrate for solution for infusionAmgen Technology (Ireland) Unlimited Company
- IcelandBekemvAmgen Technology (Ireland) UC*
- SwedenBEKEMV 300 mg Koncentrat till infusionsvätska, lösningAmgen Europe B.V.
- PolandBekemvAmgen Technology (Ireland) UC
- United StatesBKEMVAmgen Inc
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Bekemv, Soliris
- Liechtenstein · Soliris
- Norway · Bekemv, Soliris
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bd84c99c-f5fc-49eb-b190-552bf3b11d48 GET /v1/drugs/bd84c99c-f5fc-49eb-b190-552bf3b11d48?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentrate for solution for infusion",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Soliris 300 mg",
"name_fr": "Soliris 300 mg",
"name_nl": "Soliris 300 mg",
"amp_code": "SAM301856-00",
"strengths": [
"10.0000",
"5.0000"
],
"pack_count": 1,
"substances": [
"Eculizumab",
"Polysorbate 80",
"Sodium"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Eculizumab",
"authorisation_numbers": [
"EU/1/07/393/001"
]
}See everything about eculizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.